Compare Davita Inc (DVA) vs Workday Inc (WDAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Workday Inc — how do they compare? Davita Inc trades at $230.51 (market cap $14.92B), while Workday Inc trades at $139.71 (market cap $34.53B). The key difference: Workday Inc is far larger — about 2.3× Davita Inc's market cap, and Davita Inc is trading nearer its 52-week high, Workday Inc nearer its low. Which is the better fit depends on your goals.
| DVA | WDAY | |
|---|---|---|
Market Cap | $14.92B | $34.53B |
Sector | Health | Technology |
52-Week High | $235.71 | $247.69 |
52-Week Low | $103.87 | $112.55 |
Enterprise Value | $27.47B | $33.98B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
Workday (WDAY) is trading at $144.87, up 4.26% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with consistent earnings beats, 14.7% YoY subscription revenue growth, and expanding AI-driven contract values exceeding 200% year-over-year. Analyst consensus remains strongly positive with 55.55% buy ratings and a $157.30 price target, representing 8.6% upside potential from current levels.
WDAY presents a compelling growth opportunity with AI integration driving larger expansion deals and sustainable revenue growth. However, investors face risks including ongoing AI bias litigation, competitive pressures in enterprise software, and elevated valuation multiples. The stock's current technical overbought condition suggests potential near-term consolidation before further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Workday Inc
Workday is a software company that offers human capital management, or HCM, financial management, and business planning solutions. Known for being a cloud-only software provider, Workday is headquartered in Pleasanton, California. Founded in 2005, Workday now employs over 12,000 employees.
Read more on WDAY →
